PURPOSE: Recent evidence has suggested a relationship between the baseline quality of life (QOL) self-reported by patients with cancer and genetic disposition. We report an analysis exploring relationships among baseline QOL assessments and candidate genetic variations in a large cohort of patients with lung cancer. PATIENTS AND METHODS: QOL data were provided by 1,299 patients with non-small-cell lung cancer observed at the Mayo Clinic between 1997 and 2007. Overall QOL and subdomains were assessed by either Lung Cancer Symptom Scale or Linear Analog Self Assessment measures; scores were transformed to a scale of 0 to 10, with higher scores representing better status. Baseline QOL scores assessed within 1 year of diagnosis were dichotomized as clinically deficient (CD) or not. A total of 470 single nucleotide polymorphisms (SNPs) in 56 genes of three biologic pathways were assessed for association with QOL measures. Logistic regression with training/validation samples was used to test the association of SNPs with CD QOL. RESULTS: Six SNPs on four genes were replicated using our split schemes. Three SNPs in the MGMT gene (adjusted analysis, rs3858300; unadjusted analysis, rs10741191 and rs3852507) from DNA repair pathway were associated with overall QOL. Two SNPs (rs2287396 [GSTZ1] and rs9524885 [ABCC4]) from glutathione metabolic pathway were associated with fatigue in unadjusted analysis. In adjusted analysis, two SNPs (rs2756109 [ABCC2] and rs9524885 [ABCC4]) from glutathione metabolic pathway were associated with pain. CONCLUSION: We identified three SNPs in three glutathione metabolic pathway genes and three SNPs in two DNA repair pathway genes associated with QOL measures in patients with non-small-cell lung cancer.
PURPOSE: Recent evidence has suggested a relationship between the baseline quality of life (QOL) self-reported by patients with cancer and genetic disposition. We report an analysis exploring relationships among baseline QOL assessments and candidate genetic variations in a large cohort of patients with lung cancer. PATIENTS AND METHODS: QOL data were provided by 1,299 patients with non-small-cell lung cancer observed at the Mayo Clinic between 1997 and 2007. Overall QOL and subdomains were assessed by either Lung Cancer Symptom Scale or Linear Analog Self Assessment measures; scores were transformed to a scale of 0 to 10, with higher scores representing better status. Baseline QOL scores assessed within 1 year of diagnosis were dichotomized as clinically deficient (CD) or not. A total of 470 single nucleotide polymorphisms (SNPs) in 56 genes of three biologic pathways were assessed for association with QOL measures. Logistic regression with training/validation samples was used to test the association of SNPs with CD QOL. RESULTS: Six SNPs on four genes were replicated using our split schemes. Three SNPs in the MGMT gene (adjusted analysis, rs3858300; unadjusted analysis, rs10741191 and rs3852507) from DNA repair pathway were associated with overall QOL. Two SNPs (rs2287396 [GSTZ1] and rs9524885 [ABCC4]) from glutathione metabolic pathway were associated with fatigue in unadjusted analysis. In adjusted analysis, two SNPs (rs2756109 [ABCC2] and rs9524885 [ABCC4]) from glutathione metabolic pathway were associated with pain. CONCLUSION: We identified three SNPs in three glutathione metabolic pathway genes and three SNPs in two DNA repair pathway genes associated with QOL measures in patients with non-small-cell lung cancer.
Authors: J de Haes; D Curran; T Young; A Bottomley; H Flechtner; N Aaronson; J Blazeby; K Bjordal; Y Brandberg; E Greimel; J Maher; M Sprangers; A Cull Journal: Eur J Cancer Date: 2000-05 Impact factor: 9.162
Authors: V Shane Pankratz; Zhifu Sun; Jeremiah Aakre; Yan Li; Cassandra Johnson; Yolanda I Garces; Marie C Aubry; Julian R Molina; Dennis A Wigle; Ping Yang Journal: J Thorac Oncol Date: 2011-09 Impact factor: 15.609
Authors: Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts Journal: J Clin Oncol Date: 2003-12-09 Impact factor: 44.544
Authors: Adam Svobodník; Ping Yang; Paul J Novotny; Eric Bass; Yolanda I Garces; James R Jett; James A Bonner; Jeff A Sloan Journal: Mayo Clin Proc Date: 2004-08 Impact factor: 7.616
Authors: Mirjam A G Sprangers; Melissa S Y Thong; Meike Bartels; Andrea Barsevick; Juan Ordoñana; Qiuling Shi; Xin Shelley Wang; Pål Klepstad; Eddy A Wierenga; Jasvinder A Singh; Jeff A Sloan Journal: Qual Life Res Date: 2014-03-07 Impact factor: 4.147
Authors: Kimberly Alexander; Yvette P Conley; Jon D Levine; Bruce A Cooper; Steven M Paul; Judy Mastick; Claudia West; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2017-09-23 Impact factor: 3.612
Authors: Julienne E Bower; Patricia A Ganz; Michael R Irwin; Steven Castellon; Jesusa Arevalo; Steven W Cole Journal: J Clin Oncol Date: 2013-03-25 Impact factor: 44.544
Authors: Dounya Schoormans; Jingmei Li; Hatef Darabi; Yvonne Brandberg; Mirjam A G Sprangers; Mikael Eriksson; Koos H Zwinderman; Per Hall Journal: PLoS One Date: 2015-02-12 Impact factor: 3.240
Authors: Dounya Schoormans; Hatef Darabi; Jingmei Li; Yvonne Brandberg; Mikael Eriksson; Koos H Zwinderman; Mirjam A G Sprangers; Per Hall Journal: PLoS One Date: 2015-10-15 Impact factor: 3.240
Authors: Cielito C Reyes-Gibby; Jian Wang; Mary Rose T Silvas; Robert Yu; Sai-Ching J Yeung; Sanjay Shete Journal: BMC Genet Date: 2016-02-13 Impact factor: 2.797